The transcatheter pulmonary valve replacement (TPVR) is offered to patients with congenital heart diseases and high surgical risk. This case series reviewed medical records of 11 patients (10-63 years) undergoing TPVR at La Cardio between May 2021 and October 2024. Tetralogy of Fallot was the predominant congenital heart disease (54%). All procedures, performed electively, were conducted under general anesthesia with endotracheal intubation and invasive arterial monitoring. The Sapiens valve was the most commonly used (72%), with a median residual gradient of 11 mmHg and a decrease in the right ventricular systolic pressure. Complications included only one case converted to open surgery. The series demonstrated safety, a low complication rate, and positive outcomes. This study supports TPVR as a safe and effective alternative in patients with elevated surgical risk, showing promising results in the institution.